Hailong Yu

Hailong Yu

Auto-generated profile, based on publicly available information

Hailong Yu

Northern Jiangsu People’s Hospital Affiliated to Yangzhou University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Brain Research Bulletin
Verified
Journal Article
Closed access
BCBeilei Chen
Beilei Chen
LYLiu Yang
Liu Yang
JCJian Chen
Jian Chen
YCYingzhu Chen
Yingzhu Chen
LZLingling Zhang
Lingling Zhang
HYHailong Yu
Hailong Yu

17 October 2018 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
YCYingzhu Chen
Yingzhu Chen
LWLiangzhu Wang
Liangzhu Wang
LZLingling Zhang
Lingling Zhang
BCBeilei Chen
Beilei Chen
LYLiu Yang
Liu Yang
HYHailong Yu
Hailong Yu
Connexin 43 (Cx43) widely exists in all components of the neurovascular unit (NVU) and is a constituent of gap junctions and hemichannels. In physiological states, gap junctions are open for regular intercellular communication, and the hemichannels present low open probability in astrocytes. After cerebral ischemia, a large number of hemichannels are unusually opened, leading to cell swelling and even death. Most known hemichannel blockers also inhibit gap junctions and sequentially obstruct normal electrical cell-cell communication. In this study, we tested the hypothesis that Gap19, a selective Cx43-hemichannel inhibitor, exhibited neuroprotective effects on cerebral ischemia/reperfusion (I/R). An obvious improvement in neurological scores and infarct volume reduction were observed in Gap19-treated mice after brain ischemia induced by middle cerebral artery occlusion (MCAO). Gap19 treatment attenuated white matter damage. Moreover, Gap19 treatment suppressed the expression of Cx43 and Toll-like receptor 4 (TLR4) pathway-relevant proteins and prevented the overexpression of tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). To further explore downstream signaling, we established an in vitro model–oxygen glucose deprivation (OGD) to simulate ischemic conditions. Immunofluorescence staining showed that Cx43 co-existed with TLR4 in astrocytes. The hemichannel activity was increased after OGD and Gap19 could inhibit this effect on astrocytes. Gap19 substantially improved relative cell vitality and decreased the expression of Cx43, TLR4 and inflammatory cytokines in vitro. In addition, in the lipopolysaccharide (LPS) stimulation OGD model, Gap19 also exhibited a protective effect via inhibiting TLR4 pathway activation. In summary, our results showed that Gap19 exerted a neuroprotective effect after stroke via inhibition of the TLR4-mediated signaling pathway.

5 April 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
BCBeilei Chen
Beilei Chen
PCPingping Cao
Pingping Cao
XGXin Guo
Xin Guo
MYMengmei Yin
Mengmei Yin
XLXiaobo Li
Xiaobo Li
HYHailong Yu
Hailong Yu

1 October 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
XGXin Guo
Xin Guo
PCPingping Cao
Pingping Cao
XLXiongfeng Lian
Xiongfeng Lian
MHMeng Hu
Meng Hu
JZJingyi Zhao
Jingyi Zhao
YCYingzhu Chen
Yingzhu Chen

1 January 2020 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
BCBeilei Chen
Beilei Chen
YZYuanyuan Zhao
Yuanyuan Zhao
WLWei Li
Wei Li
JHJing Hang
Jing Hang
MYMengmei Yin
Mengmei Yin
HYHailong Yu
Hailong Yu
Background: Echinocystic acid (EA), a natural extract from plants of Gleditsia sinensis Lam, exhibits anti-inflammatory, antioxidant and analgesic activities in different diseases. In this study, we explored the pharmacological effects of EA on intracerebral haemorrhage (ICH) in a collagenase-induced ICH mouse model. Methods: EA (50 mg/kg, i.p. q.d) was injected after the establishment of ICH, and we measured the amount of degraded neurons in brain tissue with Fluoro-Jade C staining and the haemorrhagic injury volume with Luxol fast blue staining on day 3 after ICH. We also assessed animal behaviour by rotarod test, claw force test and modified neurological severity score (mNSS) score. The expression of apoptosis-related proteins such as Bcl-2, Bax and cleaved caspase-3 was analysed by Western blot. Results: EA reduced both the death of neurons and the volume of haemorrhagic injury after ICH. The haemorrhage infarct volume of the ICH+EA group was 31.95%±13.32% lower than that in the ICH group of mice. These findings were further confirmed with the animal behaviour results. The mNSS score of the ICH+EA treated group was 37.53%±4.80% lower than that in the ICH group. With the administration of EA after ICH, the expression of Bcl-2 was upregulated while the Bax level was downregulated. The cleaved caspase-3 level was also significantly decreased. We further investigated the neuroprotective mechanism of EA. Western blot results showed that the expression of P-AKT increased after EA treatment and decreased after LY294002, an inhibitor of the PI3K/AKT pathway, treatment. Conclusions: EA may provide neuroprotection via activation of the PI3K/AKT pathway. Given the safety of EA has been proven, further studies are required to investigate whether EA is a potential agent for the treatment of ICH.

3 June 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
LYLin Yang
Lin Yang
Guangyu LuGuangyu Lu
Guangyu Lu
HDHaiqing Diao
Haiqing Diao
YZYang Zhang
Yang Zhang
ZWZhiyao Wang
Zhiyao Wang
YLYuping LI
Yuping LI
Hospital-acquired pneumonia (HAP) is prevalent in the neuro-intensive care unit (NICU), significantly increasing susceptibility to infections with multidrug-resistant organisms (MDROs), which result in high mortality rates and substantial healthcare burdens. Recognition and intervention are paramount. This study aimed to build a prediction model for MDRO infections among NICU patients with HAP. Clinical and laboratory data were collected from the NICU of a grade-A tertiary hospital. Five machine learning models (logistic regression, classification tree, support vector machine, random forest, and K-nearest neighbor) were evaluated based on sensitivity, specificity, accuracy, and receiver operating characteristic curves. A nomogram was developed using the model that performed best in MDRO infection prediction. The performance and clinical utility were assessed using the calibration curve, Brier score, and decision curve analysis. Among 791 neurocritical care patients with HAP, 172 (21.7%) were diagnosed with MDRO infections. The prediction model established by logistic regression exhibited the best performance, with an area under the curve of 0.805. Length of NICU stay (odds ratio [OR] 1.078; 95% confidence interval [CI], 1.070–1.141; P < 0.000), number of antibiotics used (OR 1.391; 95% CI, 1.138–1.700; P = 0.001), diabetes (OR 1.775; 95% CI, 1.006–3.133; P = 0.048), and carbamide (OR 1.038; 95% CI, 1.003–1.074; P = 0.035) were significantly correlated with MDRO infections and incorporated into the nomogram. The model demonstrated good calibration (Brier score 0.137). This model can provide clinicians with a tool for prevention and management of MDRO infections in NICU patients with HAP. IMPORTANCE: Patients with hospital-acquired pneumonia (HAP) in the neuro-intensive care unit (NICU) are at a high risk of developing multidrug-resistant organism (MDRO) infections owing to complex conditions, critical illness, and frequent invasive procedures. However, studies focused on constructing prediction models for assessing the risk of MDRO infections in neurocritically ill patients with HAP are lacking at present. Therefore, this study aims to establish a reliable and easy-to-use nomogram for predicting the risk of MDRO infections in patients with HAP admitted to the NICU. Four easily accessed variables were included in the model, including length of NICU stay, number of antibiotics used, diabetes, and carbamide. This nomogram might help in the prediction and implementation of targeted interventions against infections with MDRO among patients with HAP in the NICU.